Sinopharm Group Co's ROE % for the quarter that ended in Dec. 2025 was 9.07%. Sinopharm Group Co's PB Ratio for the quarter that ended in Dec. 2025 was 0.68.
Sinopharm Group Co's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was 13.34%.
Sinopharm Group Co ROE % Adjusted to Book Value Related Terms
Sinopharm Group Co ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Sinopharm Group Co's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopharm Group Co ROE % Adjusted to Book Value Chart
SHTDF vs MCK, COR, CAH: ROE % Adjusted to Book Value Comparison
For the Medical Distribution subindustry, Sinopharm Group Co's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co ROE % Adjusted to Book Value vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 13.34% mean?
Sinopharm Group Co (SHTDF) has a ROE % Adjusted to Book Value of 13.34% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Sinopharm Group Co and its competitors.
Is Sinopharm Group Co's ROE % Adjusted to Book Value too high?
Sinopharm Group Co's current ROE % Adjusted to Book Value is 13.34%. Overall, Sinopharm Group Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's ROE % Adjusted to Book Value compare to MCK and COR?
Sinopharm Group Co's ROE % Adjusted to Book Value of 13.34% can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Distribution company?
A good ROE % Adjusted to Book Value depends on the Medical Distribution industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Sinopharm Group Co and its competitors. Sinopharm Group Co's current ROE % Adjusted to Book Value is 13.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.03, compared to a current price of $2.29 — trading 24.5% below its estimated fair value. The current ROE % Adjusted to Book Value is 13.34%. Sinopharm Group Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Sinopharm Group Co (SHTDF), the current ROE % Adjusted to Book Value is 13.34% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDF) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $2.29 is trading 24.5% below its estimated GF Value™ of $3.03.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDF:
ROE % Adjusted to Book Value: 13.34%
GF Value™: $3.03 vs. price of $2.29 (24.5% below fair value)
No single metric tells the full story. See the SHTDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
78GF Score
Get the complete analysis for SHTDF
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDF has been successfully added to your 
